Grace Therapeutics, Inc. Impairment of Intangible Assets (Excluding Goodwill)
Grace Therapeutics, Inc. (GRCE) reported Impairment of Intangible Assets (Excluding Goodwill) of $13.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-13
- Grace Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $13.53M.
- Grace Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month |
|---|---|
| 2026-06-30 | $13.53M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |